Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

HYPERTENSION, PULMONARY

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Pulmonary arterial hypertension is a progressive and lethal rare disease. This pathology is characterized by an increase in pressure at the pulmonary arteries. PAH is classified as idiopathic, heritable, drugs or toxins-induced or is associated with connective tissue pathway. A new molecule, selexipag, used to treat PAH, is now available. It’s an oral non-prostanoid selective in prostacyclin receptor. It improves hemodynamic parameters and reduces morbidity and mortality among patients with pulmonary arterial hypertension. This work focus on the comparison between this drug and the current classes in order to establish in position in the treatment of this complex pathology. L'hypertension artérielle pulmonaire est une maladie rare d'évolution progressive et mortelle caractérisée par une élévation de la pression sanguine au niveau des artères pulmonaires. Ce groupe comprend les formes idiopathiques, familiales, induites par l'utilisation de drogues ou de toxines et associées à une connectivité, une cardiopathie congénitale, une hypertension portale, le SIDA ou schistosomiase. Pour traiter les formes sévères de cette pathologie, on dispose actuellement de trois classes molécules ciblant la voie de l'endothéline, la voie du NO-GMPc et la voie de la prostacycline. Une nouvelle molécule, le selexipag, utilisée pour traiter l'hypertension artérielle pulmonaire, arrive sur marché. C'est un agoniste oral non prostanoïde spécifique des récepteurs IP de la prostacycline. Il améliore les paramètres hémodynamiques et diminue la morbi-mortalité chez les patients atteints d'HTAP.Ce travail porte sur la comparaison entre ce médicament et les classes actuelles afin d'établir son positionnement dans le traitement de cette pathologie complexe.

Hypertension, Pulmonary --- Selexipag --- Antihypertensive Agents

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Pulmonary arterial hypertension (PAH) is a rare condition; yet this very rarity can be a disadvantage when it comes to treatment, making PAH difficult to diagnose, and resulting in suboptimal patient care. Furthermore, the global burden of PAH remains poorly understood and largely underestimated, as PAH commonly presents as a comorbidity with such conditions as systemic sclerosis, COPD, idiopathic pulmonary fibrosis and left-heart dysfunction. However, in recent years there has been significant investment in developing new therapies for PAH, and treatment for this previously neglected disease

Hypertension, Pulmonary. --- Pulmonary artery. --- Pulmonary hypertension.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Heart Defects, Congenital --- Child --- Infant --- Hypertension, Pulmonary

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Hypertension, Pulmonary --- Adaptation, Physiological --- Hypertrophy, Left Ventricular --- physiopathology